Novo Nordisk remains financially strong, but pricing pressures and CagriSema challenges limit near-term upside. Find out why ...

Novo Nordisk has said it is discontinuing selling its popular, best-selling insulin brand in India and will instead promote ...

After selling off a portion of its diabetes care business last year, Ypsomed is now fully exiting the diabetes care business ...

The drug company Eli Lilly is suing four telehealth companies for allegedly selling copies made by compounding pharmacies of ...

CHRISTINA Park had struggled with yo-yo dieting for years – trapped in a vicious cycle of losing 4 to 8lb, then putting on 6 ...

Indian diabetic population on Human Mixtard concerned on changes in insulin therapy: Nandita Vijayasimha, Bengaluru Thursday, April 24, 2025, 08:00 Hrs [IST] India’s diabetic po ...

Ozempic is a prescription medication given by injection under the skin for people ... under the skin once weekly using a prefilled Ozempic pen. Your doctor will show you how to use your pen ...

Discover Mounjaro Tirzepatide's impact on obesity in India post its March launch. Get insights on effectiveness against ...

In obesity, it will compete with Novo Nordisk’s GLP-1 agonist Wegovy (semaglutide), which ... available in the original singe-dose pen-injector format. Mounjaro has already been launched in ...

The new vials – priced at $399 and $549, respectively, for a month's supply – are a lower-cost alternative to the current injector pen formulation ... with the latter's Wegovy (semaglutide ...